Quilizumab

Quilizumab is a monoclonal antibody designed for the treatment of asthma and allergies. It was developed by Genentech, a biotechnology company based in the United States. Quilizumab targets the M1-prime segment of membrane-expressed Immunoglobulin M (IgM), leading to the depletion of IgM memory B cells.

Development and Clinical Trials

Quilizumab was initially developed by Genentech for the treatment of asthma and allergies. The drug works by targeting and depleting IgM memory B cells, which are responsible for the production of antibodies that cause allergic reactions.

In 2014, a Phase II clinical trial was conducted to evaluate the efficacy of Quilizumab in patients with uncontrolled allergic asthma. The results of the trial showed that Quilizumab reduced the frequency of asthma exacerbations in patients, but did not significantly improve lung function or asthma control.

Mechanism of Action

Quilizumab works by binding to the M1-prime segment of membrane-expressed IgM. This binding triggers a process called Antibody-dependent cellular cytotoxicity (ADCC), which leads to the depletion of IgM memory B cells. By reducing the number of these cells, Quilizumab can decrease the production of antibodies that cause allergic reactions.

Potential Side Effects

As with any medication, Quilizumab has the potential to cause side effects. In clinical trials, the most common side effects reported were nasopharyngitis (inflammation of the nose and throat), headache, and upper respiratory tract infection. However, the overall safety profile of Quilizumab was considered acceptable.

See Also

• Monoclonal antibodies
• Asthma
• Allergies
• Clinical trial
• Immunoglobulin M
• B cells